Specifically, in adult metabolic disorders such as diabetes, cancer, or obesity, our findings here suggest that drugs that target mitochondrial SRC [64,65,66,67] could hold promise as therapeutic potential and might warrant further study for their ability to alter ATP levels and restore the BHI ratio to physiological levels. The gene discussed is SRC; the disease is metabolic disease.